2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - New Orleans Theatre B
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Biological Processes, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

707 A phase 1, open-label study of UB-VV400 +/- rapamycin in relapsed or refractory (R/R) B-cell malignancies

Xiaoyan Qu, MD, PhD, Yan Xu, MD2, Luke Walker, MD3, Christine Dehner4, Jeffrey Teoh, PhD5, Sanmei Wang, MD, PhD6, Haorui Shen, MD7, Yingshuai Wang, PhD8, Jie Chen, MD9, Dehui Zou, MD10, Lei Fan, MD11, Liang Huang, MD12
1 Jiangsu Provincial Hospital, Nanjing, China
2 Institute of Hematology & Blood Diseases Hospital, Tianjin, China
3 Umoja Biopharma, Seattle, Washington, United States
4 Umoja Biopharma, Seattle, Washington, United States
5 Umoja Biopharma, Seattle, Washington, United States
6 Jiangsu Provincial Hospital, Nanjing, China
7 Jiangsu Provincial Hospital, Nanjing, China
8 IASO Biotherapeutics, Nanjing, China
9 IASO Biotherapeutics, Nanjing, China
10 Institute of Hematology & Blood Diseases Hospital, Tianjin, China
11 Jiangsu Provincial Hospital, Nanjing, China
12 Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Autologous, ex vivo-manufactured chimeric antigen receptor (CAR) T cells have demonstrated clinical activity in hematologic malignancies, with approved products available for relapsed/refractory (R/R) B-cell malignancies (BCMs), including large B-cell lymphoma (LBCL). However, limited manufacturing capacity, need for apheresis/lymphodepletion, treatment failure to prior ex?vivo CAR T therapy, and degree of patient fitness needed to wait for CAR T manufacturing all pose significant challenges to the field, presenting significant unmet medical need. 

UB-VV400 is a third-generation, self-inactivating, replication-incompetent lentiviral vector (LVV) investigational drug product comprising an envelope with cocal fusion glycoprotein and surface engineered with a membrane-bound multidomain fusion (MDF) protein. The MDF protein contains T-cell adhesion, activation, and costimulation components that promote both T-cell tropism and activation signals to support effective CAR T-cell generation. UB-VV400 is designed to generate fully human CD22-directed CAR T cells in vivo without apheresis and lymphodepletion, thus addressing the delivery limitations of currently available autologous ex vivo CAR T therapies. Its mechanism of action involves in vivo T-cell transduction to generate CD22-targeted CAR T cells that mediate cell killing and express the rapamycin-activated cytokine receptor (RACR) system which, in the presence of rapamycin, provides specific pro-survival and expansion signals to transduced cells. CD22 is an attractive therapeutic target because its expression is restricted to B?cells, including normal and malignant B cells. Moreover, CD22 offers an alternative target for patients who progress or relapse after exposure to CD19-directed therapies.  

Study UB-VV400CI001 (NCT06743503) is a Phase 1, dose-finding study of UB-VV400 administered intravenously (IV) +/- rapamycin in adults with R/R BCMs, including LBCL. Dose finding uses a Bayesian optimal interval (BOIN) design. Major eligibility criteria include adults with R/R LBCL or high-risk follicular lymphoma (FL) who have standard organ function, measurable disease per Lugano 2014, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1, and no prior allogeneic transplant. Primary objectives include characterizing the safety profile and determining the maximum tolerated/administered dose and recommended Phase 2 dose. Antitumor activity (overall response rate) is assessed as a secondary objective. Durability of response and pharmacokinetics (PK)/pharmacodynamics (Pd) are evaluated as exploratory objectives. To date, 11?participants with R/R LBCL following a median of 2 prior lines of therapy (range, 2 to 5) have been treated on study with UB-VV400 at doses up to 30×108 TU +/- rapamycin. Dose-limiting toxicity was observed in 1 of 11 treated participants (a serious adverse event [SAE] of Grade 4 infusion-related reaction [IRR]; 30 × 108 TU + rapamycin). Lower-grade (Grade 1-2) IRRs were reported for 3 other participants. A second participant in the 30×108 TU UB-VV400 + rapamycin group experienced an SAE (Grade 4 platelet count decreased); no other SAEs were reported at any dose level. Cytokine release syndrome was reported for 2 participants (Grade 1; both treated with 30×108 TU + rapamycin). Grade 3 prolonged cytopenia (anemia) was reported for 1?participant (30×108 TU UB-VV400 + rapamycin). No neurologic toxicity and no other toxicities of concern were observed. Clinical responses have been observed in 4 of 9 efficacy-evaluable participants (2 PRs, 2?CRs), including all 3?evaluable participants treated at 30×108 TU plus rapamycin, resulting in an objective response rate (ORR) of 100% at the highest dose evaluated with rapamycin. Both participants with CR at 30×108 TU + rapamycin were in continued response at the data cutoff (one at Day 90 and one at Day 29). Peak CAR T-cell expansion was observed on Days 13 to 15. Clinical follow-up and dose finding are ongoing. Key long-term follow-up of translational and clinical parameters will be available at the time of presentation.  

Lei Fan, MD: No relevant conflicts of interest to declare.